Anti-Microbial Resistance (AMR) is a pandemic which threatens modern medicine. There is a lack of effective drug treatment due to the slow pace, high cost and low achievable sales prices
Combinations of old antimicrobials such as Helperby’s colistin and azidothymidine are a possible alternative to developing new chemical entities, because they cost one tenth of the price. A Global
The fight against antibiotic resistance is real and something we all have a responsibility in tackling. As traditional drugs stop working, what steps are being taken now?
Using its antibiotic renewable technology, Helperby Therapeutics is developing a new class of antibiotics with activity against multi drug-resistant bacteria, including strains with transferable resistance to carbapenems and colistin.
Antibiotic resistance is at a crossroad. In the world today, deaths in low income countries from Antimicrobial Resistance (AMR) are predicted to rise dramatically by 2050. We know how to stop
The combination is azidothymidine (AZT), which is a new class antibacterial, and low dose colistin. The combination is active against all three WHO Critical Priority Pathogens. In addition, AZT and
Helperby Therapeutics has announced Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE),
The combination is azidothymidine (AZT), a new class antibacterial, and low dose colistin. The combination is active against all three WHO Critical Priority Pathogens. AZT and colistin act synergistically against